ABBV-295

DRUG4 trials

Sponsors

AbbVie

Conditions

Healthy VolunteerObesityOverweight

Phase 1

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

RecruitingNCT07291232

Start: 2025-11-19End: 2027-03-01Target: 80Updated: 2026-08-07

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

CompletedNCT07414784

AbbVieHealthy Volunteer

Start: 2026-02-11End: 2026-08-04Updated: 2026-08-31

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Active, not recruitingNCT07514260

AbbVieHealthy Volunteer

Start: 2026-03-31End: 2027-01-01Updated: 2026-08-14

Phase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

RecruitingNCT07752979

AbbVieObesity, Overweight

Start: 2026-08-04End: 2028-03-01Target: 360Updated: 2026-09-18